NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) IN MEN WITH TYPE 2 DIABETES
|
|
- Aubrey Goodwin
- 8 years ago
- Views:
Transcription
1 NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) IN MEN WITH TYPE 2 DIABETES D. Bakalov 1, M. Boyanov 1, G. Sheinkova 1, L. Vezenkova 1, G. Prodanova 2, V. Christov 1 1 Endocrinology Clinic 2 Sonography unit Central Consultation Policlinic, Alexandrovska University Hospital, Department Internal Medicine, Medical University Sofia Key words: metabolic syndrome, type 2 diabetes, non-alcoholic fatty liver disease Contact details: D. Bakalov, Endocrinology Clinic, Alexandrovska UMHAT, 1 Sv. G. Sofiiski Blvd.,Sofia 1431, fax: , dbakalov@abv.bg Abstract: The non-alcoholic fatty liver disease (NAFLD) is implicated in the pathogenesis of insulin resistance, of the metabolic syndrome (MS) and type 2 diabetes mellitus (DM 2). The objective was to study the prevalence of NAFLD in men with diabetes type 2. Materials and methods: This is a retrospective, cross-sectional, observational study. We analyzed data from hospitalized patients: 80 men with diabetes type 2 (mean age 59.0 ± 10.7 years). Body weight, height, BMI, waist circumference, systolic and diastolic blood pressure were analyzed, as well as laboratory parameters such as fasting plasma glucose (FPG), glycated hemoglobin A1c, serum lipids, liver enzymes (AST, ALT, GGT). The liver shape, size and sonographic pattern were documented by abdominal ultrasonography. Results: 11.2% of type 2 diabetic men had ALA > 40 IU/L and 35.0% - GGT >35 IU/L. 40% of the men with DM 2 had liver steatosis. Between the subgroups (with/without NAFLD) the differences were significant only for BMI (р=0.027), diastolic blood pressure (р=0.031), and GGT (р=0.044). If a diagnostic threshold for NAFLD is set on 30 UI/L, the sensitivity of ALT is around 29% and that of GGT around 33%. Discussion: This study revealed a high prevalence of sonographic signs for liver steatosis in men with diabetes type 2 and emphasized on the need for sonography screening in such patients for the diagnosing of NAFLD. Original Article Introduction In Bulgaria, non-alcoholic fatty liver disease (NAFLD) is often referred to as the non-alcoholic steatohepatitis syndrome (NASH-syndrome). The NAFLD is assumed to be the hepatic manifestation of the metabolic syndrome. 1,2 Numerous studies have confirmed a bilateral relationship - NAFLD prevalence is higher among people with type 2 diabetes and metabolic syndrome 3,4 and vice versa - the prevalence of diabetes among people with this liver pathology is higher. 5,6,7 NAFLD is associated with increased risk for cardiovascular diseases, hepatocellular carcinoma and total mortality. 8,9,10,11,12 Different therapeutic approaches for treatment of NAFLD are explored from lifestyle changes to drugs influencing elements of the insulin resistance and the metabolic syndrome. 13 The prevalence of the NAFLD in the general population is high - about 15-30% and even higher among people with type 2 diabetes or metabolic syndrome. 4,14,15,16 The prevalence of diabetes and pre-diabetic conditions among people with known non-alcoholic fatty liver disease has been the predominant subject of research in our country in the last decade. 5,17 The objective of this study is to determine the 31
2 NAFLD in Men with Type 2 Diabetes prevalence of the non-alcoholic fatty liver disease by abdominal ultrasound and the associated clinical and laboratory parameters among men with type 2 diabetes mellitus. Materials and methods The presented study is a retrospective, cross-sectional and observational one. We analyzed data from 80 hospitalized men with diabetes type 2, admitted between 2006 and 2008, with mean age 59.0 ± 10.7 (from 36 to 85) The Diabetes mellitus in the study participants had a mean duration of 10 years (minimum 1 year, maximum 30 years) and was primarily treated with metformin (70% of men), sulfonylureas (40%), insulin (60%), and other oral agents (40%). 70% of the men with type 2 diabetes met the IDF 18 criteria of the metabolic syndrome - an increased waist circumference (> 94 cm) plus fasting glycaemia 5.6 mmol/l, or dyslipidemia (triglycerides 1.7 mmol/l, HDL - cholesterol <1.1 mmol/l), or arterial hypertension (blood pressure above 130/85 mm Hg). After taking the patient s history (including previous liver diseases and alcohol intake), physical examination was performed and the following anthropometric variables were included in the analysis - height, weight, body mass index, waist circumference. They are summarized in Table 1. The main inclusion criterion for the data analysis was the presence of abdominal ultrasonography with documented assessment of the shape, size and echogeneicity of the liver. The latter examination was conducted at random, but only with a small percentage of the hospitalized patients diagnosed with diabetes mellitus. The abdominal ultrasonography was carried out by the same experienced specialist, using a Versa Pro apparatus (Siemens, Germany) and a convex 3.0 and 5.0 MHz transducer. We kept to the internationally adopted criteria and scale for echogenicity of the liver parenchyma, the visibility of the diaphragm and the intrahepatic vessels, allowing the diagnosis diffuse increased echogenicity - probable fatty liver. The diagnosis probable NAFLD was suggested in the absence of a history or evidence of hepatitis, other significant hepatobiliary disease, medications that affect the liver or regular alcohol intake (daily> 30 g of concentrate). If there was a positive history of a liver noxious factor, the patient data were not included in the analysis (30 people failed this criterion). Laboratory tests included morning fasting plasma glucose, glycated hemoglobin A1c, serum lipids, liver enzymes (AST, ALT, GGT) - as part of the routine biochemical panels in the Central Clinical Laboratory of UMHAT Alexandrovska - Sofia. All these parameters were measured after at least 12 hours of fasting. Reference values for AST and ALT were 5 to 40 IU/l, and for GGT - <35 IU/L. Blood pressure was determined by an aneroid sphygmomanometer on the dominant arm as mean of two consecutive measurements. The statistical analysis was performed on SPSS 13.0 software program (SPSS Institute, Chicago, IL) and included descriptive statistics, analysis of frequency distribution, cross tables and ANOVA. The level of significance was accepted as p Results The summarized results from the biochemical panel of the participants with diabetes mellitus are presented in table 2. The mean systolic blood pressure was ± 14.2 mm Hg, while the mean diastolic ± 9.7 mm Hg. 11.2% of type 2 diabetic men had ALT > 40 IU/L and 35.0% - GGT> 35 IU/L. The mean index AST/ALT was 0.83 ± 0.31 (minimum 0.45, maximum ) and ratio over 1.0 had 10.0%. 40% of the diabetics had liver steatosis. Subgroup differences (with/without NAFLD) were significant only for the BMI (р=0.027), the diastolic blood pressure (р=0.031), and the GGT-values (р=0.044). The relation between the increasing metabolic parameters and the prevalence of the liver steatosis is presented in table 3. If the diagnostic threshold for NAFLD is 30 UI/L, the sensitivity of ALT is around 29% and that of GGT around 33%. The increase of the threshold lowers the 32
3 sensitivity. Thus, if the threshold for both enzymes is > 60 IU/L, the sensitivity decreases to 5% for ALT and 8% for GGT. Discussion The Non-alcoholic fatty liver disease (NAFLD, NASH) affects a significant proportion of the general population and is associated with a variety of features of the metabolic syndrome. Its role in the progression of atherosclerosis and carcinogenesis has been also demonstrated. Worldwide, more epidemiological data are collected on the prevalence of this type of liver pathology. The reported prevalence among healthy persons is around 16%, 23%, 27%, 32.6% 6,9,19, while among type 2 diabetics - much higher: 49.0% to 69.4% 1,20. S. Jimba et al. established increase in prevalence of NAFLD with the impairment of glucose homeostasis - from 27% in healthy persons to 43% in impaired fasting glycaemia and 62% in newly diagnosed with diabetes type Thus, our data on the prevalence of hepatic steatosis, being 40% in manifested diabetes type 2, are lower than most literature data. So far, the NAFLD prevalence data has been scarce in Bulgaria. Mateva L. et al. found that if non-alcoholic fatty liver is present, the prevalence of metabolic syndrome is between 52% and 76% depending on the used definition, while in the manifested diabetes type %. 3,17 In our study, we paid special attention to the liver enzymes levels. A. Dassanayake et al. reported that the double increase of ALT above the upper normal limit is associated with increased risk of NAFLD. 21 Elevations of ALT, however, are associated with an extensive differential diagnosis, which was reported in detail by C.-H. Chen et al. 22 Despite the fact we used an extremely low threshold criteria - lower than the upper reference limit, our data revealed relatively low sensitivity of increased ALT and GGT for detecting NAFLD - about 20-30%. With the increase of the threshold, sensitivity decreased significantly. A threshold at 1½ times the upper reference limit of both enzymes leads to a decrease in sensitivity below 10%. In a study of S. Zelber-Sagi et al., the sensitivity of the increased ALT is 33
4 NAFLD in Men with Type 2 Diabetes of the same magnitude, compared to the abdominal ultrasonography - 8.2%. 23 From these results it appears obvious that the increase of ALT and GGT is a neither sufficiently sensitive, nor a sufficiently specific criterion for the diagnosis of NAFLD. We were unable to confirm significant differences between subgroups with and without steatosis on the basis of the examined clinical and laboratory parameters - only in terms of BMI, diastolic blood pressure and values of GGT. The literature also does not present convincing evidence of a direct quantitative relationship between NAFLD, obesity, insulin resistance, dyslipidemia and hyperglycemia in both sexes. 4,6,16 Our study poses the question about the use of the abdominal ultrasonography in the diagnosis of NAFLD. Histological examination of liver bioptate remains the gold standard for defining simple steatosis from steatohepatitis with a potential for significant fibrosis or cirrhosis. 19 Fatty infiltration of the liver, however, can be demonstrated with ultrasonography - although not the most accurate, but the most widely available method with sufficiently good specificity. 20 Histological evaluation of liver tissue is indicated primarily in cases of concurrent elevations of AST and at least doubled ALT-values. 24 Among our participants, there were none with a significant increase in all transaminases, thereby no such evaluation was required. When analyzing our data the limitations of our study should be kept in mind. It was conducted with a relatively modest number of participants, selected among hospitalized patients. The exclusion of alcohol or viral genesis of the liver pathology was based mainly on previous history and the available medical records. Conclusions Non-alcoholic fatty liver disease (NAFLD) is associated with increased mortality, cardiovascular morbidity, hepatocellular carcinogenesis and involvement in the pathogenesis of the metabolic syndrome and type 2 diabetes mellitus. It is worth focusing research efforts in the direction of NAFLD because of the potentials for treating that liver disease and the scarce available data in Bulgaria. Acknowledgements The authors would like to thank Svetla Kecheva - a nurse at the Endocrinology Clinic, for assistance in data collection. 34
5 Bibliography: 1. El-Zayadi, A.-R. Hepatic steatosis: A benign disease or a silent killer. World J Gastroenterol. 2008; 14(26): Raman M., J. Allard. Nonalcoholic fatty liver disease: A clinical approach and review. Can. J Gastroenterol. 2006; 20(5): Dimitrova, V., A. Alexiev, L. Mateva. Elevated liver enzymes, fatty liver and signs of metabolic syndrome in healthy volunteers. Bulgarian hepatogastroenterology. 2008; 10(2): Leite, N. C., G.F. Salles, A.L.E. Araujo, et al. Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver International. 2009; 20(1): Mateva L. Insulin resistance and diabetes in chronic liver disease. Dissertation, Medical University Sofia, Riquelme, A., M. Arrese, A. Soza, et al. Non-alcoholic fatty liver disease and its association with obesity, insulin resistance and increased serum levels of C-reactive protein in Hispanics. Liver International. 2009; 20(1): Wong, V., A. Hui, S. Tsang, et al. Prevalence of undiagnosed diabetes and postchallenge hyperglycaemia in Chinese patients with non-alcoholic fatty liver disease. Alimentary Pharmacology & Therapeutics. 2006; 24(8): Ivanova, R., D. Stanchev, A. Alexiev, et al. Cardiovascular risk in non-alcoholic fatty liver disease (NAFLD). Comparative assessment of the risk of IHD according to Framingham risk score in healthy subjects and NAFLD. Bulgarian hepatogastroenterology. 2008; 10(2): Choi, S.-Y., D. Kim, H. Kim, et al. The relation between non-alcoholic fatty liver disease and the risk of coronary heart disease in Koreans. American Journal of Gastroenterology. 2009; 104(8): Donato, F., U. Gelatti, R. Limina, et al. Southern Europe as an example of interaction between various environmental factors: a systematic review of the epidemiologic evidence. Oncogene. 2006; 25(27): Targher, G. Non-alcoholic fatty liver disease, the metabolic syndrome and the risk of cardiovascular disease: the plot thickens. Diabetic Medicine. 2007; 24(1): Targher, G., L.Bertolini, R. Padovani, et al. Increased prevalence of cardiovascular disease in Type 2 diabetic patients with nonalcoholic fatty liver disease. Diabetic Medicine. 2006; 23(4): Lingvay, I., P. Raskin, L.S. Szczepaniak. Effect of Insulin and Metformin Combination on Hepatic Steatosis. in Type 2 Diabetes. J Diabetes Complications. 2007; 21(3): Gupte, P., D. Amarapurkar, A. Deepak, et al. Nonalcoholic steatohepatitis in type 2 diabetes mellitus. Journal of Gastroenterology & Hepatology. 2004; 19(8): Jimba, S., T. Nakagami, M. Takahashi, et al. Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults. Diabetic Medicine. 2005; 22(9): Park, S. H., W.K. Jeon, S.H. KIM, et al. Prevalence and risk factors of non-alcoholic fatty liver disease among Korean adults. Journal of Gastroenterology & Hepatology. 2006; 21(1): Mateva, L., V. Dimitrova, A. Alexiev, C de Mey. Are the healthy clinical research volunteers really healthy? I. Ultrasonography signs of steatosis and metabolic syndrome in healthy volunteers. JCM. 2009; 1: Alberti, K.G., P. Zimmet, J. Shaw. The metabolic syndrome a new worldwide definition. Lancet. 2005, 366(9491), Hubscher, S. Role of liver biopsy in the assessment of non-alcoholic fatty liver disease. European Journal of Gastroenterology & Hepatology. 2004, 16(11): Joy, D., V. Thava, B. Scott. Diagnosis of fatty liver disease: is biopsy necessary? European Journal of Gastroenterology & Hepatology. 2003; 15(5): Dassanayake, A. S., A. Kasturiratne, S. Rajindrajith, et al. Prevalence and risk factors for non-alcoholic fatty liver disease among adults in an urban Sri Lankan population. Journal of Gastroenterology & Hepatology. 2009; 24(7): Chen, C.H.,, M.H. Huang, J.C. Yang, et al. Prevalence and etiology of elevated serum alanine aminotransferase level in an adult population in Taiwan. Journal of Gastroenterology & Hepatology. 2007; 22(9): Zelber-Sagi, S., D. Nitzan-Kaluski, Z. Halpern, et al. Prevalence of primary non-alcoholic fatty liver disease in a population-based study and its association with biochemical and anthropometric measures. Liver International. 2006; 26(7): de Ledinghen, V., M. Combes, H. Trouette, et al. Should a liver biopsy be done in patients with subclinical chronically elevated transaminases? European Journal of Gastroenterology & Hepatology. 2004; 16(9):
Non-alcoholic fatty liver disease: Prognosis and Treatment
Non-alcoholic fatty liver disease: Prognosis and Treatment Zachary Henry, M.D. Assistant Professor UVA Gastroenterology & Hepatology October 28, 2015 Overview Case Presentation Prognosis Effects of fibrosis
More information1. PATHOPHYSIOLOGY OF METABOLIC SYNDROME
1. PATHOPHYSIOLOGY OF METABOLIC SYNDROME Izet Aganović, Tina Dušek Department of Internal Medicine, Division of Endocrinology, University Hospital Center Zagreb, Croatia 1 Introduction The metabolic syndrome
More informationNP/PA Clinical Hepatology Fellowship Summary of Year-Long Curriculum
OVERVIEW OF THE FELLOWSHIP The goal of the AASLD NP/PA Fellowship is to provide a 1-year postgraduate hepatology training program for nurse practitioners and physician assistants in a clinical outpatient
More informationMetabolic Syndrome Overview: Easy Living, Bitter Harvest. Sabrina Gill MD MPH FRCPC Caroline Stigant MD FRCPC BC Nephrology Days, October 2007
Metabolic Syndrome Overview: Easy Living, Bitter Harvest Sabrina Gill MD MPH FRCPC Caroline Stigant MD FRCPC BC Nephrology Days, October 2007 Evolution of Metabolic Syndrome 1923: Kylin describes clustering
More informationRole of Body Weight Reduction in Obesity-Associated Co-Morbidities
Obesity Role of Body Weight Reduction in JMAJ 48(1): 47 1, 2 Hideaki BUJO Professor, Department of Genome Research and Clinical Application (M6) Graduate School of Medicine, Chiba University Abstract:
More informationTYPE 2 DIABETES MELLITUS: NEW HOPE FOR PREVENTION. Robert Dobbins, M.D. Ph.D.
TYPE 2 DIABETES MELLITUS: NEW HOPE FOR PREVENTION Robert Dobbins, M.D. Ph.D. Learning Objectives Recognize current trends in the prevalence of type 2 diabetes. Learn differences between type 1 and type
More informationObesity in the United States Workforce. Findings from the National Health and Nutrition Examination Surveys (NHANES) III and 1999-2000
P F I Z E R F A C T S Obesity in the United States Workforce Findings from the National Health and Nutrition Examination Surveys (NHANES) III and 1999-2000 p p Obesity in The United States Workforce One
More informationNASH: It is not JUST a Fatty Liver. Karen F. Murray, M.D. Director of Hepatobiliary Program Children s Hospital and Regional Medical Center
NASH: It is not JUST a Fatty Liver Karen F. Murray, M.D. Director of Hepatobiliary Program Children s Hospital and Regional Medical Center Stages of Fatty Liver Disorders Fatty Liver 16-35% of Western
More informationDR. Trinh Thi Kim Hue
TYPE 2 DIABETES IN THE CHILD AND ADOLESCENT DR. Trinh Thi Kim Hue CONTENTS Definition Diagnosis Treatment Comorbidities and Complications Comorbidities and Complications Screening for T2D References DEFINITION
More informationNon-alcoholic fatty liver disease in diabetics prevalence and predictive factors in a multiracial hospital clinic population in Malaysia
bs_bs_banner doi:10.1111/jgh.12204 HEPATOLOGY Non-alcoholic fatty liver disease in diabetics prevalence and predictive factors in a multiracial hospital clinic population in Malaysia Wah-Kheong Chan,*
More informationNon Alcoholic Steato-Hepatitis (NASH)
Non Alcoholic Steato-Hepatitis (NASH) DISCLAIMER NEITHER THE PUBLISHER NOR THE AUTHORS ASSUME ANY LIABILITY FOR ANY INJURY AND OR DAMAGE TO PERSONS OR PROPERTY ARISING FROM THIS WEBSITE AND ITS CONTENT.
More informationPrimary Care Guidance Program: Non-Alcohol related Fatty Liver Disease (NAFLD) Guidance on Management in Primary Care
Primary Care Guidance Program: Non-Alcohol related Fatty Liver Disease (NAFLD) Guidance on Management in Primary Care This advice has been developed to help GPs with shared care of patients with Non- Alcohol
More informationProtein Intake in Potentially Insulin Resistant Adults: Impact on Glycemic and Lipoprotein Profiles - NPB #01-075
Title: Protein Intake in Potentially Insulin Resistant Adults: Impact on Glycemic and Lipoprotein Profiles - NPB #01-075 Investigator: Institution: Gail Gates, PhD, RD/LD Oklahoma State University Date
More informationClinical Research on Lifestyle Interventions to Treat Obesity and Asthma in Primary Care Jun Ma, M.D., Ph.D.
Clinical Research on Lifestyle Interventions to Treat Obesity and Asthma in Primary Care Jun Ma, M.D., Ph.D. Associate Investigator Palo Alto Medical Foundation Research Institute Consulting Assistant
More informationPrevention of and the Screening for Diabetes Part I Insulin Resistance By James L. Holly, MD Your Life Your Health The Examiner January 19, 2012
Prevention of and the Screening for Diabetes Part I Insulin Resistance By James L. Holly, MD Your Life Your Health The Examiner January 19, 2012 In 2002, SETMA began a relationship with Joslin Diabetes
More informationNew Medicare Preventive
New Medicare Preventive Services Screening Tests You Can Perform in the Office Charles B. Root, PhD Medicare is finally getting serious about preventive services. Until now, the limited preventive testing
More informationBoehringer Ingelheim- sponsored Satellite Symposium. HCV Beyond the Liver
Boehringer Ingelheim- sponsored Satellite Symposium HCV Beyond the Liver HCV AS A METABOLIC MODIFIER: STEATOSIS AND INSULIN RESISTANCE Francesco Negro University Hospital of Geneva Switzerland Clinical
More informationThe Prevalence and Determinants of Undiagnosed and Diagnosed Type 2 Diabetes in Middle-Aged Irish Adults
The Prevalence and Determinants of Undiagnosed and Diagnosed Type 2 Diabetes in Middle-Aged Irish Adults Seán R. Millar, Jennifer M. O Connor, Claire M. Buckley, Patricia M. Kearney, Ivan J. Perry Email:
More informationNon-alcoholic Fatty Liver Disease, as a Possible Independent Risk Factor for Obliterative Arteriopathy
RESEARCH ARTICLE Acta Medica Marisiensis 2012;58(5):341-345 Non-alcoholic Fatty Liver Disease, as a Possible Independent Risk Factor for Obliterative Arteriopathy Szalman Krisztina Borbála, Puskás A 2
More informationDiabetes and Stroke. Understanding the connection between diabetes and the increased risk of stroke
Diabetes and Stroke Understanding the connection between diabetes and the increased risk of stroke Make the Connection Almost 26 million people in the U.S. roughly 8 percent of the population have diabetes.
More informationHow To Treat Dyslipidemia
An International Atherosclerosis Society Position Paper: Global Recommendations for the Management of Dyslipidemia Introduction Executive Summary The International Atherosclerosis Society (IAS) here updates
More informationType 2 Diabetes Mellitus and Insulin resistance syndrome in Children
Type 2 Diabetes Mellitus and Insulin resistance syndrome in Children Anil R Kumar MD Pediatric Endocrinology MCV/VCU, Richmond VA Introduction Type 2 diabetes mellitus (T2 DM) has increased in children
More informationImproving cardiometabolic health in Major Mental Illness
Improving cardiometabolic health in Major Mental Illness Dr. Adrian Heald Consultant in Endocrinology and Diabetes Leighton Hospital, Crewe and Macclesfield Research Fellow, Manchester University Metabolic
More informationTreating Patients with PRE-DIABETES David Doriguzzi, PA-C First Valley Medical Group. Learning Objectives. Background. CAPA 2015 Annual Conference
Treating Patients with PRE-DIABETES David Doriguzzi, PA-C First Valley Medical Group Learning Objectives To accurately make the diagnosis of pre-diabetes/metabolic syndrome To understand the prevalence
More informationPowerPoint Lecture Outlines prepared by Dr. Lana Zinger, QCC CUNY. 12a. FOCUS ON Your Risk for Diabetes. Copyright 2011 Pearson Education, Inc.
PowerPoint Lecture Outlines prepared by Dr. Lana Zinger, QCC CUNY 12a FOCUS ON Your Risk for Diabetes Your Risk for Diabetes! Since 1980,Diabetes has increased by 50 %. Diabetes has increased by 70 percent
More informationBACKGROUND MEDIA INFORMATION Fast facts about liver disease
BACKGROUND MEDIA INFORMATION Fast facts about liver disease Liver, or hepatic, disease comprises a wide range of complex conditions that affect the liver. Liver diseases are extremely costly in terms of
More informationHigh Blood Cholesterol
National Cholesterol Education Program ATP III Guidelines At-A-Glance Quick Desk Reference 1 Step 1 2 Step 2 3 Step 3 Determine lipoprotein levels obtain complete lipoprotein profile after 9- to 12-hour
More informationIS VITAMIN E SAFE TO USE?
Vitamin E & Fatty Liver IS VITAMIN E SAFE TO USE? Nonalcoholic Fatty Liver Disease (NAFLD) & Nonalcoholic Steatohepatitis (NASH) Prevalence: 5.7-16.5% 57 5 in US Usually diagnosed in 40-60 y/o s Non-significant
More informationTYPE 2 DIABETES IN CHILDREN DIAGNOSIS AND THERAPY. Ines Guttmann- Bauman MD Clinical Associate Professor, Division of Pediatric Endocrinology, OHSU
TYPE 2 DIABETES IN CHILDREN DIAGNOSIS AND THERAPY Ines Guttmann- Bauman MD Clinical Associate Professor, Division of Pediatric Endocrinology, OHSU Objectives: 1. To discuss epidemiology and presentation
More informationBody Composition & Longevity. Ohan Karatoprak, MD, AAFP Clinical Assistant Professor, UMDNJ
Body Composition & Longevity Ohan Karatoprak, MD, AAFP Clinical Assistant Professor, UMDNJ LONGEVITY Genetic 25% Environmental Lifestyle Stress 75% BMI >30 OBESE 25-30 OVERWEIGHT 18-25 NORMAL WEIGHT 18
More informationAbnormal Liver Function. Dr William Alazawi MA(Cantab) PhD MRCP Senior Lecturer and Consultant in Hepatology Queen Mary, University of London
Abnormal Liver Function Dr William Alazawi MA(Cantab) PhD MRCP Senior Lecturer and Consultant in Hepatology Queen Mary, University of London Does Liver Disease Matter? Mortality in England & Wales Liver-related
More informationAlanine aminotransferase (serum, plasma)
Alanine aminotransferase (serum, plasma) 1 Name and description of analyte 1.1 Name of analyte Alanine aminotransferase (ALT) 1.2 Alternative names Systematic name L alanine:2 oxoglutarate aminotransferase
More information2.1 AST can be measured in heparin plasma or serum. 3 Summary of clinical applications and limitations of measurements
Aspartate aminotransferase (serum, plasma) 1 Name and description of analyte 1.1 Name of analyte Aspartate aminotransferase (AST) 1.2 Alternative names Systematic name L aspartate:2 oxoglutarate aminotransferase
More informationAbsolute cardiovascular disease risk assessment
Quick reference guide for health professionals Absolute cardiovascular disease risk assessment This quick reference guide is a summary of the key steps involved in assessing absolute cardiovascular risk
More informationDiabetes, Type 2. RelayClinical Patient Education Sample Topic Diabetes, Type 2. What is type 2 diabetes? How does it occur?
What is type 2 diabetes? Type 2 diabetes is a disorder that happens when your body does not make enough insulin or is unable to use its own insulin properly. The inability to use insulin is called insulin
More informationPatterns of abnormal LFTs and their differential diagnosis
Patterns of abnormal LFTs and their differential diagnosis Professor Matthew Cramp South West Liver Unit and Peninsula Schools of Medicine and Dentistry, Plymouth Summary liver function / liver function
More informationDISCLOSURES RISK ASSESSMENT. Stroke and Heart Disease -Is there a Link Beyond Risk Factors? Daniel Lackland, MD
STROKE AND HEART DISEASE IS THERE A LINK BEYOND RISK FACTORS? D AN IE L T. L AC K L AN D DISCLOSURES Member of NHLBI Risk Assessment Workgroup RISK ASSESSMENT Count major risk factors For patients with
More informationPlasma Testosterone Level in Male Patients with Metabolic Syndrome
Med. J. Cairo Univ., Vol. 77, No. 1, June: 351-357, 2009 www.medicaljournalofcairouniversity.com Plasma Testosterone Level in Male Patients with Metabolic Syndrome NASHWA EL-SARRAF, M.D. and AMR EL-HADIDY,
More informationDiabetes and Heart Disease
Diabetes and Heart Disease Diabetes and Heart Disease According to the American Heart Association, diabetes is one of the six major risk factors of cardiovascular disease. Affecting more than 7% of the
More informationDIABETES YOUR GUIDE TO
YOUR GUIDE TO DIABETES b What is diabetes? b Type 2 diabetes prevention b Prevention checklist b Living with diabetes b Complications b Terms to know b Resources To promote and protect the health of Canadians
More informationGetting Off the Chronic Disease Merry-Go-Round: What s the Weight of the Research?
Getting Off the Chronic Disease Merry-Go-Round: What s the Weight of the Research? Jody Dushay, MD MMSc Beth Israel Deaconess Medical Center Boston, MA Session 445 No disclosures Disclosure Jody Dushay,
More informationUnderstanding diabetes Do the recent trials help?
Understanding diabetes Do the recent trials help? Dr Geoffrey Robb Consultant Physician and Diabetologist CMO RGA UK Services and Partnership Assurance AMUS 25 th March 2010 The security of experience.
More informationDo You Know the Health Risks of Being Overweight?
Do You Know the Health Risks of Being Overweight? U.S. Department of Health and Human Services NATIONAL INSTITUTES OF HEALTH WIN Weight-control Information Network What are the risks to my health from
More informationAlcoholic Liver Disease and Its Relationship with Metabolic Syndrome
Research and Reviews Alcoholic Liver Disease and Its Relationship with Metabolic Syndrome JMAJ 53(4): 236 242, 2010 Hiromasa ISHII,* 1 Yoshinori HORIE,* 2 Yoshiyuki YAMAGISHI,* 3 Hirotoshi EBINUMA* 3 Abstract
More informationDeterminants of Abnormal Liver Function Tests in Diabetes Patients in Myanmar
International Journal of Diabetes Research 2012, 1(3): 36-41 DOI: 10.5923/j.diabetes.20120103.02 Determinants of Abnormal Liver Function Tests in Diabetes Patients in Myanmar Han Ni 1,*, Htoo Htoo Kyaw
More informationNova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Diabetes sections of the Guidelines)
Cardiovascular Health Nova Scotia Guideline Update Nova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Diabetes sections of the Guidelines) Authors: Dr. M. Love, Kathy Harrigan Reviewers:
More informationDifferential Diagnosis of NAFLD- A Short Summary:
Differential Diagnosis of NAFLD- A Short Summary: Almost a fifth of our general pediatric population is now classified as overweight in the United States. When such children present with elevated liver
More informationTHE STUDY OF NEWLY DISCOVERED CASES OF DIABETES MELLITUS IN BIHOR COUNTY
Analele UniversităŃii din Oradea Fascicula:Ecotoxicologie, Zootehnie şi Tehnologii de Industrie Alimentară, 2012 THE STUDY OF NEWLY DISCOVERED CASES OF DIABETES MELLITUS IN BIHOR COUNTY *University of
More informationComparative Levels of ALT, AST, ALP and GGT in Liver associated Diseases
Available online at wwwpelagiaresearchlibrarycom European Journal of Experimental Biology, 2013, 3(2):280-284 ISSN: 2248 9215 CODEN (USA): EJEBAU Comparative Levels of ALT, AST, ALP and GGT in Liver associated
More informationThe Link Between Obesity and Diabetes The Rapid Evolution and Positive Results of Bariatric Surgery
The Link Between Obesity and Diabetes The Rapid Evolution and Positive Results of Bariatric Surgery Michael E. Farkouh, MD, MSc Peter Munk Chair in Multinational Clinical Trials Director, Heart and Stroke
More informationAntiretroviral treatment is Associated with increased Arterial Stiffness in Sub- Saharan African HIV-1 Infected Patients: A cross- Sectional Study
Antiretroviral treatment is Associated with increased Arterial Stiffness in Sub- Saharan African HIV-1 Infected Patients: A cross- Sectional Study Titus F. Msoka Supervisors Marceline van Furth Yvo Smulders
More informationInsulin Resistance and PCOS: A not uncommon reproductive disorder
Insulin Resistance and PCOS: A not uncommon reproductive disorder Joyce L. Ross, MSN, CRNP, CS, FNLA, FPCNA Diplomate Accrediation Council for Clinical Lipidology President Preventive Cardiovascular Nurses
More informationPredictors of Non-Alcoholic Fatty Liver Disease in y e Diabetes
Int J Endocrinol Metab 2007; 2: 61-69 Predictors of Non-Alcoholic Fatty Liver Disease in y e Diabetes ORIGINAL ARTICLE Hosseinpanah F, Rambod M, Sadeghi L Obesity Research Center, Research Intitute for
More informationEvaluation of abnormal LFT in the asymptomatic patient. Son Do, M.D. Advanced Gastroenterology Vancouver, WA
Evaluation of abnormal LFT in the asymptomatic patient Son Do, M.D. Advanced Gastroenterology Vancouver, WA Definition of chronic, abnormally elevated LFT Elevation of one or more of the following for
More informationGuidelines for the management of hypertension in patients with diabetes mellitus
Guidelines for the management of hypertension in patients with diabetes mellitus Quick reference guide In the Eastern Mediterranean Region, there has been a rapid increase in the incidence of diabetes
More informationCME Test for AMDA Clinical Practice Guideline. Diabetes Mellitus
CME Test for AMDA Clinical Practice Guideline Diabetes Mellitus Part I: 1. Which one of the following statements about type 2 diabetes is not accurate? a. Diabetics are at increased risk of experiencing
More informationVascular Risk Reduction: Addressing Vascular Risk
Vascular Risk Reduction: Addressing Vascular Risk Vascular Risk Reduction (VRR) Welcome! Presentation & Activities Focus: Managing known risk factors for vascular disease. Engage, collaborate and have
More informationThe National Cholesterol Education Program s Adult
NHLBI/AHA Conference Proceedings Definition of Metabolic Syndrome Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition
More informationNon-Alcoholic Fatty Liver Disease
Non-Alcoholic Fatty Liver Disease Information for patients and families UHN Read this information to learn: what non-alcoholic fatty liver disease is what causes it how it s treated how to prevent it where
More informationBarriers to Healthcare Services for People with Mental Disorders. Cardiovascular disorders and diabetes in people with severe mental illness
Barriers to Healthcare Services for People with Mental Disorders Cardiovascular disorders and diabetes in people with severe mental illness Dr. med. J. Cordes LVR- Klinikum Düsseldorf Kliniken der Heinrich-Heine-Universität
More informationLiver means Life. Why this manifesto? We are eager to ensure. that we can contribute. to society as much. as possible, and we. are equally keen to
Manifesto by the European Liver Patients Association (ELPA) on policy measures against chronic liver disease 2014 to 2019 Why this manifesto? Every five years European voters get the opportunity to have
More informationCardiovascular Disease Risk Factors Part XII Insulin Resistance By James L. Holly, MD Your Life Your Health The Examiner September 15, 2005
Cardiovascular Disease Risk Factors Part XII By James L. Holly, MD Your Life Your Health The Examiner September 15, 2005 As we approach the end of our extended series on cardiovascular disease risk factors,
More informationTwo Cases of Non-Alcoholic Steato-Hepatitis Developing from Simple Fatty Liver
case series Two Cases of Non-Alcoholic Steato-Hepatitis Developing from Simple Fatty Liver Soo Ryang Kim, Taisuke Nakajima, Kenji Ando, Keiji Mita, Katsumi Fukuda Department of Gastroenterology, Kobe Asahi
More informationTitle: A low level of serum total testosterone is independently associated with nonalcoholic fatty liver disease
Author's response to reviews Title: A low level of serum total testosterone is independently associated with nonalcoholic fatty liver disease Authors: Sunmi Kim (arpsm@naver.com) Hyuktae Kwon (hyuktae@gmail.com)
More informationPublished Quarterly Mangalore, South India ISSN 0972-5997 Volume 4, Issue 1; January-March 2005
Published Quarterly Mangalore, South India ISSN 0972-5997 Volume 4, Issue 1; January-March 2005 Original Article Genetic Association Between Insulin Resistance And Total Cholesterol In Type 2 Diabetes
More information嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯
The Clinical Efficacy and Safety of Sodium Glucose Cotransporter-2 (SGLT2) Inhibitors in Adults with Type 2 Diabetes Mellitus 嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯 Diabetes Mellitus : A group of diseases characterized
More informationNutrition. Type 2 Diabetes: A Growing Challenge in the Healthcare Setting NAME OF STUDENT
1 Nutrition Type 2 Diabetes: A Growing Challenge in the Healthcare Setting NAME OF STUDENT 2 Type 2 Diabetes: A Growing Challenge in the Healthcare Setting Introduction and background of type 2 diabetes:
More informationEstimation of Diagnosis and Treatment Costs of Non-Alcoholic Fatty Liver Disease: A Two-Year Observation
Estimation of Diagnosis and Treatment Costs of Non-Alcoholic Fatty Liver Disease: A Two-Year Observation Mohammad Ebrahim Ghamar Chehreh 1, Mohsen Vahedi 2, Mohammad Amin Pourhoseingholi 3, Sara Ashtari
More informationOverview of Diabetes Management. By Cindy Daversa, M.S.,R.D.,C.D.E. UCI Health
Overview of Diabetes Management By Cindy Daversa, M.S.,R.D.,C.D.E. UCI Health Objectives: Describe the pathophysiology of diabetes. From a multiorgan systems viewpoint. Identify the types of diabetes.
More informationCOST ANALYSIS OF ANTIDIABETIC DRUGS FOR DIABETES MELLITUS OUTPATIENT IN KODYA YOGYAKARTA HOSPITAL
Malaysian Journal of Pharmaceutical Sciences, Vol. 5, No. 1, 19 23 (2007) COST ANALYSIS OF ANTIDIABETIC DRUGS FOR DIABETES MELLITUS OUTPATIENT IN KODYA YOGYAKARTA HOSPITAL TRI MURTI ANDAYANI* AND IKE IMANINGSIH
More informationHDL Cholesterol Subfractions and the Effect of Testosterone Replacement in Hypogonadism
HDL Cholesterol Subfractions and the Effect of Testosterone Replacement in Hypogonadism E. Bolu 1, A. Sonmez 1, S. Tapan 2, A. Taslipinar 1, A. Aydogdu 1, C. Meric 1, Y. Basaran 1, G. Uckaya 1, M. Serdar
More informationSt Lucia Diabetes and Hypertension Screening and Disease Management Programs
St Lucia Diabetes and Hypertension Screening and Disease Management Programs Michael Graven, MD, MSc,, MPH, FAAP Health Informatics and Neonatal Pediatrics Dalhousie University Halifax, Nova Scotia CANADA
More informationMETABOLIC SYNDROME IN A CORRECTIONS POPULATION TREATED WITH ANTIPSYCHOTICS
METABOLIC SYNDROME IN A CORRECTIONS POPULATION TREATED WITH ANTIPSYCHOTICS Andrew M. Cislo, PhD Megan J. Ehret, PharmD, MS, BCPP Robert L. Trestman, MD, PhD Kirsten Shea, MBA www.uchc.edu Background Metabolic
More informationMY TYPE 2 DIABETES NUMBERS
BLOOD SUGAR MANAGEMENT GUIDE MY TYPE 2 DIABETES NUMBERS Understanding and Tracking the ABCs of Type 2 Diabetes 1 BLOOD MY TYPE SUGAR 2 DIABETES MANAGEMENT ABC NUMBERS GUIDE When you have type 2 diabetes,
More informationIntroduction. Pathogenesis of type 2 diabetes
Introduction Type 2 diabetes mellitus (t2dm) is the most prevalent form of diabetes worldwide. It is characterised by high fasting and high postprandial blood glucose concentrations (hyperglycemia). Chronic
More informationGuidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes
Guidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes U.S. Department of Health and Human Services Food and Drug Administration Center
More informationCHAPTER V DISCUSSION. normal life provided they keep their diabetes under control. Life style modifications
CHAPTER V DISCUSSION Background Diabetes mellitus is a chronic condition but people with diabetes can lead a normal life provided they keep their diabetes under control. Life style modifications (LSM)
More informationCardiovascular disease physiology. Linda Lowe-Krentz Bioscience in the 21 st Century October 14, 2011
Cardiovascular disease physiology Linda Lowe-Krentz Bioscience in the 21 st Century October 14, 2011 Content Introduction The number 1 killer in America Some statistics Recommendations The disease process
More informationHypertension and Diabetes Status. 2011 Bangladesh Demographic and Health Survey
Hypertension and Diabetes Status 2011 Bangladesh Demographic and Health Survey Methodology and Sampling Total 18,000 households were selected nationwide (207 in urban and 393 in rural areas) One-third
More informationREPORT ON DIABETES i
AFRICAN UNION UNION AFRICAINE UNIÃO AFRICANA AU CONFERENCE OF MINISTERS OF HEALTH (CAMH6) Sixth Ordinary Session, 22-26 April 2013, Addis Ababa, ETHIOPIA CAMH/Exp/6(VI) iv THEME: The Impact of Non-Communicable
More informationDiabetes and Obesity in Children. Janie Berquist, RN, BSN, MPH, CDE Children s Mercy Hospitals and Clinics Kansas City, MO
Diabetes and Obesity in Children Janie Berquist, RN, BSN, MPH, CDE Children s Mercy Hospitals and Clinics Kansas City, MO Diabetes and Obesity in Children What is Diabetes? How are Diabetes and Obesity
More informationHepatic steatosis, the accumulation of lipids in. Long-Term Follow-up of Patients With NAFLD and Elevated Liver Enzymes
Long-Term Follow-up of Patients With NAFLD and Elevated Liver Enzymes Mattias Ekstedt, 1 Lennart E. Franzén, 2 Ulrik L. Mathiesen, 3 Lars Thorelius, 4 Marika Holmqvist, 5 Göran Bodemar, 1 and Stergios
More informationDiabetes. Patient Education. What you need to know. Diabetes Facts. Improving Health Through Education. What is Diabetes?
Diabetes What you need to know Diabetes Facts More than 3 million Canadians have diabetes (Canadian Diabetes Association, 2009). It is the 4th leading cause of death in the world (CDA, 2009). Patient Education
More informationNUTRITION IN LIVER DISEASES
NUTRITION IN LIVER DISEASES 1. HEPATITIS: Definition: - Viral inflammation of liver cells. Types: a. HAV& HEV, transmitted by fecal-oral route. b. HBV & HCV, transmitted by blood and body fluids. c. HDV
More informationStatins and Risk for Diabetes Mellitus. Background
Statins and Risk for Diabetes Mellitus Kevin C. Maki, PhD, FNLA Midwest Center for Metabolic & Cardiovascular Research and DePaul University, Chicago, IL 1 Background In 2012 the US Food and Drug Administration
More informationHepatology Guidelines for Primary Care November 2011
Common requests for hepatology opinion/advice 1. Abnormal LFTs (is this fatty liver?) 2. Fatty Liver Disease (is this serious liver disease?) 3. Abnormal liver ultrasound 4. Alcohol related liver disease
More informationHow To Know If You Have Microalbuminuria
3 PREVALENCE AND PREDICTORS OF MICROALBUMINURIA IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: A CROSS-SECTIONAL OBSERVATIONAL STUDY Dr Ashok S Goswami *, Dr Janardan V Bhatt**; Dr Hitesh Patel *** *Associate
More informationCorrespondence should be addressed to Farid Saad; farid.saad@bayer.com
International Journal of Endocrinology, Article ID 683515, 15 pages http://dx.doi.org/10.1155/2014/683515 Clinical Study Effects of Long-Term Testosterone Therapy on Patients with Diabesity : Results of
More informationESC/EASD Pocket Guidelines Diabetes, pre-diabetes and cardiovascular disease
Diabetes, prediabetes and cardiovascular disease Classes of recommendations Levels of evidence Recommended treatment targets for patients with diabetes and CAD Definition, classification and screening
More informationDiabetes mellitus. Lecture Outline
Diabetes mellitus Lecture Outline I. Diagnosis II. Epidemiology III. Causes of diabetes IV. Health Problems and Diabetes V. Treating Diabetes VI. Physical activity and diabetes 1 Diabetes Disorder characterized
More informationWHAT DOES DYSMETABOLIC SYNDROME MEAN?
! WHAT DOES DYSMETABOLIC SYNDROME MEAN? Dysmetabolic syndrome (also referred to as syndrome X, insulin resistance syndrome, and metabolic syndrome ) is a condition in which a group of risk factors for
More informationCHEM 1406 BSA/BMI Measurement Laboratory (revised 01/03//06) BSA, Body Surface Area
CHEM 1406 BSA/BMI (revised 01/03//06) BSA, Body Surface Area See pages 105-110 of dosage text for equations, calculations and adult nomogram See pages 270-273 of dosage calculation text for pediatric nomogram
More informationThe first endoscopically-delivered device therapy for obese patients with type 2 diabetes
DIABETES WEIGHT ENDOBARRIER THERAPY The first endoscopically-delivered device therapy for obese patients with type 2 diabetes Restore the metabolic health of your patients with EndoBarrier Therapy. Dual
More informationInsulin is a hormone produced by the pancreas to control blood sugar. Diabetes can be caused by too little insulin, resistance to insulin, or both.
Diabetes Definition Diabetes is a chronic (lifelong) disease marked by high levels of sugar in the blood. Causes Insulin is a hormone produced by the pancreas to control blood sugar. Diabetes can be caused
More informationAn Overview and Guide to Healthy Living with Type 2 Diabetes
MEETING YOUR GOALS An Overview and Guide to Healthy Living with Type 2 Diabetes MEETING YOUR GOALS This brochure was designed to help you understand the health goals to live a healthy lifestyle with type
More informationHow To Determine The Prevalence Of Microalbuminuria
Research Journal of Pharmaceutical, Biological and Chemical Sciences Prevalence of Microalbuminuria in relation to HbA1c among known Type2 Diabetic Patients in Puducherry population Muraliswaran P 1 *,
More information4/4/2013. Mike Rizo, Pharm D, MBA, ABAAHP THE PHARMACIST OF THE FUTURE? METABOLIC SYNDROME AN INTEGRATIVE APPROACH
METABOLIC SYNDROME AN INTEGRATIVE APPROACH AN OPPORTUNITY FOR PHARMACISTS TO MAKE A DIFFERENCE Mike Rizo, Pharm D, MBA, ABAAHP THE EVOLUTION OF THE PHARMACIST 1920s 1960s 2000s THE PHARMACIST OF THE FUTURE?
More informationIs Insulin Effecting Your Weight Loss and Your Health?
Is Insulin Effecting Your Weight Loss and Your Health? Teressa Alexander, M.D., FACOG Women s Healthcare Associates www.rushcopley.com/whca 630-978-6886 Obesity is Epidemic in the US 2/3rds of U.S. adults
More informationTHE NEW INTERCEPT STRATEGY FOR OCA AND THE IMPACT OF GENFIT- GFT505 MARKET
THE NEW INTERCEPT STRATEGY FOR OCA AND THE IMPACT OF GENFIT- GFT505 MARKET (G DIVRY- March the 22th, 2015) The new strategy of Intercept for OCA seems to be revealed in their communication last Friday
More informationNHS Diabetes Prevention Programme (NHS DPP) Non-diabetic hyperglycaemia. Produced by: National Cardiovascular Intelligence Network (NCVIN)
NHS Diabetes Prevention Programme (NHS DPP) Non-diabetic hyperglycaemia Produced by: National Cardiovascular Intelligence Network (NCVIN) Date: August 2015 About Public Health England Public Health England
More information